Wells Fargo & Company Clearside Biomedical, Inc. Transaction History

Wells Fargo & Company

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.08 - $1.58 $548 - $802	-508 Reduced 91.04%	50 $0
Q1 2024 May 10, 2024	BUY	$1.2 - $2.02 $111 - $187	93 Added 20.0%	558 $0
Q4 2023 Feb 09, 2024	BUY	$0.68 - $1.18 $16 - $28	24 Added 5.44%	465 $0
Q3 2023 Nov 13, 2023	BUY	$0.82 - $1.27 $10 - $16	13 Added 3.04%	441 $0
Q2 2023 Aug 15, 2023	BUY	$0.97 - $1.48 $23 - $35	24 Added 5.94%	428 $0
Q1 2023 May 12, 2023	BUY	$0.93 - $1.66 $5 - $9	6 Added 1.51%	404 $0
Q4 2022 Feb 13, 2023	BUY	$1.0 - $1.5 $9 - $13	9 Added 2.31%	398 $0
Q3 2022 Nov 14, 2022	BUY	$1.08 - $1.83 $1 - $1	1 Added 0.26%	389 $0
Q2 2022 Aug 12, 2022	BUY	$1.3 - $2.49 $439 - $841	338 Added 676.0%	388 $0
Q1 2022 May 16, 2022	SELL	$1.35 - $2.88 $1 - $2	-1 Reduced 1.96%	50 $0
Q4 2021 Feb 14, 2022	SELL	$2.72 - $5.72 $829 - $1,744	-305 Reduced 85.67%	51 $0
Q3 2021 Nov 15, 2021	SELL	$4.83 - $7.2 $77 - $115	-16 Reduced 4.3%	356 $2,000
Q2 2021 Aug 16, 2021	BUY	$2.32 - $5.38 $176 - $408	76 Added 25.68%	372 $2,000
Q1 2021 May 13, 2021	BUY	$2.24 - $4.25 $49 - $93	22 Added 8.03%	296 $1,000
Q4 2020 Feb 09, 2021	SELL	$1.32 - $2.74 $55,773 - $115,773	-42,253 Reduced 99.36%	274 $1,000
Q3 2020 Nov 05, 2020	SELL	$1.45 - $2.0 $4,028 - $5,556	-2,778 Reduced 6.13%	42,527 $66,000
Q2 2020 Aug 13, 2020	BUY	$1.55 - $2.41 $69,818 - $108,556	45,044 Added 17258.24%	45,305 $85,000
Q1 2020 May 14, 2020	BUY	$1.32 - $3.77 $344 - $983	261 New	261 $0

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $52.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.